655 Followers on Owler
Sangamo focuses on research, development and commercialization of deoxyribonucleic acid binding proteins for therapeutic gene regulation...
Read moreSangamo focuses on research, development and commercialization of deoxyribonucleic acid binding proteins for therapeutic gene regulation...
Read more
1995
PublicIndependent CompanyNASDAQSGMO
News
Dec 12, 2022
MarketScreener
Sangamo: Sangamo Therapeutics : 22-1566 ASH BIVV003 Phase I-II Interim results
Nov 20, 2022
Seeking Alpha
Sangamo: Sangamo Therapeutics: Ready To Dust Off My Dormant Position Ahead Of A Pivotal 2023
Nov 17, 2022
MarketScreener
Sangamo: Sangamo Therapeutics : PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING
Nov 04, 2022
Owler
Sangamo Therapeutics, Inc.: Sangamo's revenue changed from $114.16M in Jun 2022 to $112.06M in Sep 2022
Oct 27, 2022
MarketScreener
Sangamo: Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
Oct 12, 2022
Benzinga
Sangamo: Sangamo Touts Additional Positive Data For Fabry Gene Therapy Candidate
Oct 12, 2022
MarketScreener
Sangamo: Sangamo Therapeutics : Update Regarding Isaralgagene Civaparvovec (Fabry Disease) - Form 8-K
Oct 12, 2022
Life Care News
Sangamo: Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients
Jul 22, 2022
Pharamceutical Technology
Sangamo: Sangamo's cell therapy receives EC orphan medicinal product designation
Jun 01, 2022
FinanzNachrichten
Sangamo: Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Competitors
1
2
3
4
5
6
7
8
9
10
Looking for similar companies to Sangamo?
Sangamo Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$112.1M
Sangamo's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 438.7M. Over the last four quarters, Sangamo's revenue has decreased by 5.5%. Specifically, in Q3 2022's revenue was $26.5M; in Q2 2022, it was $29.4M; in Q1 2022, it was $28.2M; in Q4 2021, Sangamo's revenue was $28M.
Sangamo News
Sangamo Press Releases
Sangamo Headquarters
Sangamo Summary
ABOUT
Overview
Sangamo focuses on research, development and commercialization of deoxyribonucleic acid binding proteins for therapeutic gene regulation. Sangamo was founded in 1995. Sangamo's headquarters is located in Brisbane, California, USA 94005. Sangamo's Pr...CEO
Sangamo's President & CEO, Sandy Macrae, currently has an approval rating of 79%. Sangamo's primary competitors are uniQure, REGENXBIO & Asklepios.Website
sangamo.comCompetitors
View 15 Sangamo competitors here.Acquisitions
View 2 companies acquired by Sangamo here.Investments
Recent investment data cannot be found related to SangamoFrequently Asked Questions about Sangamo
When was Sangamo founded?
Sangamo was founded in 1995Who is Sangamo's CEO?
Sangamo's CEO is Sandy MacraeHow much revenue does Sangamo generate?
Sangamo generates $112.1M in revenueHow much funding does Sangamo have?
Sangamo has historically raised $71.5M in funding
Where is Sangamo's headquarters?
Sangamo's headquarters is in Brisbane California, USAHow many employees does Sangamo have?
Sangamo has 430 employeesWhat sector does Sangamo operate in?
Sangamo is in BiotechnologyWho are Sangamo's competitors?
Sangamo's top competitors are uniQure, REGENXBIO, Asklepios